Albert Seymour
President and CEO
Seamless Therapeutics
Seamless Therapeutics develops disease-modifying gene editing candidates using programmable recombinase technology. This approach enables precise, large DNA edits within the genome without introducing unintended mutations. The company aims to expand the therapeutic potential of gene editing to treat severe genetic diseases.
- Biotechnology
Updated 15 days ago
Funding
Raised to date
$25MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current gene editing technologies often lack the precision and efficiency needed to correct the genetic causes of severe diseases, particularly when large DNA edits are required. Existing methods can introduce unintended mutations or fail to achieve the desired therapeutic outcome due to limitations in targeting and enzymatic activity.
Solution
Seamless Therapeutics is developing a gene editing platform based on programmable recombinases, a class of enzymes capable of making large, precise DNA deletions or insertions anywhere in the genome. The company's technology reprograms recombinases to target specific DNA sequences, enabling efficient and accurate gene editing without introducing additional mutations. This approach aims to address the underlying genetic causes of severe diseases by precisely correcting faulty genes and restoring normal cellular function. Seamless Therapeutics is developing a pipeline of disease-modifying product candidates across a broad spectrum of indications to expand the therapeutic potential of gene editing.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing gene therapies for severe genetic diseases.
Features
- Programmable recombinases for precise and efficient gene editing
- Ability to perform large DNA deletions or insertions without off-target effects
- Zinc-finger dependent recombinases for improved target site specificity
- Disease-modifying product candidates across a broad spectrum of indications
- Technology to reprogram Large Serine Recombinases (LSRs) targeting sequences in the human genome, enabling seamless, efficient and precise DNA sequence integration.